TOP TEN perturbations for 38683_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38683_s_at
Selected probe(set): 214919_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38683_s_at (214919_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):3.18816Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):2.9703608Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.7993422Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):-2.715415Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Relative Expression (log2-ratio):-2.6732483Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
TC-71 / TC-32
Relative Expression (log2-ratio):2.382965Number of Samples:6 / 6
| Experimental | TC-71 |
| Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code: | |
| Control | TC-32 |
| Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code: |
renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) / renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.3827896Number of Samples:2 / 18
| Experimental | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). |
expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (neuroendocrine carcinoma; primary)
Relative Expression (log2-ratio):2.3512897Number of Samples:2 / 6
| Experimental | expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS). | |
| Control | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.2755442Number of Samples:2 / 3
| Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.2469482Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
Organism: Homo sapiens
Gene: 38683_s_at
Selected probe(set): 208773_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38683_s_at (208773_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-4.3452034Number of Samples:2 / 4
| Experimental | R547 study 1 (24h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-3.6747723Number of Samples:2 / 2
| Experimental | zalypsis study 2 |
| OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated OPM1 cell sample |
| OPM1 multiple myeloma cells untreated. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):3.529871Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.4853106Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-3.3472528Number of Samples:3 / 3
| Experimental | echinomycin study 1 |
| Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
| Control | deferoxamine study 5 |
| Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.1245508Number of Samples:4 / 4
| Experimental | R547 study 3 (6h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.9648848Number of Samples:4 / 4
| Experimental | R547 study 1 (6h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.730338Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.6543293Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.5350742Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |